The RheumNow EULAR Week in Review – 16 June 2017
Dr. Jack Cush reviews some of the highlights from the past week at EULAR 2017 - June 16, 2017.
Follow RheumNow's expanded coverage from EULAR 2017 in Madrid.
Rheumatic IRAEs Gaining Speed
Today I was fortunate to be a part of a From Bench to Bedside session on the topic of controlling the balance between cancer and autoimmunity, chaired by Drs. Leonard Calabrese and Xavier Mariette.
Suspending Methotrexate for Influenza Vaccination
Vaccinating our rheumatoid arthritis patients against influenza every year is a safety priorty. However immunosuppressive therapies pose a challenge to vaccine administration as their use can hamper vaccine immunogenicity.
Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis
The NEJM reports success when using mepolizumab (anti-IL-5 monoclonal antibody) in a 52 week study of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Actemra - First FDA Approved Drug for Giant Cell Arteritis
Genentech announced on May 22 that subcutaneous (sc) tocilizumab (TCZ) was granted FDA approval for Giant Cell Arteritis (GCA) – also known as temporal arteritis.
Rituximab May Benefit Rheumatoid Lung
A single-center, uncontrolled, 10-year follow-up study of rheumatoid arthritis (RA) shows that treatment with rituximab (RTX) in patients with RA-related interstitial lung disease (RA-ILD) may forestall ILD progression.
The RheumNow Week in Review – 21 April 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Paradoxical Toxicities with TNF Inhibitors
Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.
The RheumNow Week in Review – 14 April 2017
Dr. Jack Cush reviews the past week's news, articles and advances from RheumNow.com.
Steroids, DMARDs and Biologics have Same Low Risk of Infection During Pregnancy
Pregnancy imposes a potential risk for infection.
The RheumNow Week in Review – 24 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Sjogren's Syndrome Foundation's 2017 Sjogren's Treatment Guidelines
Dr. Steven Carsons and an expert committee of the Sjogren's Syndrome Foundation have published a clinical practice guidelines (CPGs) and recommendations for the managment of Sjögren's syndrome.
Social
I've heard people say FDG uptake on PET/CT in PMR/GCA is just a correlate of systemic inflamm.
Look at the uptake intensity (SUVmax) vs inflamm markers in n=65 PET/CT in GCA. There's no pattern whatsoever.
Not just an expensive ESR!
@FreemanHospital SAT0272 #EULAR2020 @RheumNow https://t.co/D4xAZC7KmO
David Liew @drdavidliew ( View Tweet )
5 years 6 months ago
To truly address adherence, you need to understand what is impairing it, and tailor an approach to overcome those barriers.
Great to see this articulated in EULAR recommendations re: non-adherence - a big factor in our therapeutic outcomes!
EULAR projects #EULAR2020 @RheumNow https://t.co/0pazcDFTuV
David Liew @drdavidliew ( View Tweet )
5 years 6 months ago
Is there subclinical GCA in PMR pts?
50 consecutive PMR pts had vascular USS. 27/50 had GCA vascular uptake, of which 10 had no GCA symptoms at all.
Is PMR sometimes just the tip of the GCA iceberg? Do the aSx USS+ pts get GCA Sx eventually?
Bonn SAT0254 #EULAR2020 @RheumNow https://t.co/UmsixY29Qh
David Liew @drdavidliew ( View Tweet )
5 years 6 months ago
GCA and cancer: it's been hard to tease apart, lots of cofounders. We've needed large cohorts with comparators & detail.
Large Israeli database says there are links
(EMR/claims/prescribing combined, n = 4.4m w validated incident GCA set). If so, why?
OP0143 #EULAR2020 @RheumNow https://t.co/kSPGnxNjah
David Liew @drdavidliew ( View Tweet )
5 years 6 months ago
#EULAR2020 Prof. T Domer: baricitinib show promise in phase II trial for SLE: Microarray analysis noted reduction in IFN signature; however, the reduction did not correlate w/SLEDAI-2K or SRI4 clinical response @RheumNow https://t.co/cW4egzSnAs
k dao @KDAO2011 ( View Tweet )
5 years 6 months ago
#EULAR2020 Most innovative! Vaccination with IFNa-kinoid to induce anti-IFNa antibodies to treat SLE (results of phase IIb trial). https://t.co/rM0z23ieQW @RheumNow https://t.co/OYMdDZl6sb
k dao @KDAO2011 ( View Tweet )
5 years 6 months ago
#EULAR2020 Dr. Kimme Hyrich reviews the EULAR #COVID19 Registry "Most individuals with rheumatic diseases receiving immunosuppressive therapies recover from COVID19" @rheumnow https://t.co/EdVLUMyHhF
k dao @KDAO2011 ( View Tweet )
5 years 6 months ago
#EULAR2020 panel on #COVID19 spec. situatns:
1. German regtry: very few preg rheum pts w/CV19; cases mild.
2. No info how CV19 affects APS
3. Very few ped rheum cases of CV19- cases mild; outcomes sim to gen peds pop
4. Most rheum pts w/CV19 good prognosis @rheumnow https://t.co/LQVdzJKCgu
k dao @KDAO2011 ( View Tweet )
5 years 6 months ago
#eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h
Olga Petryna @DrPetryna ( View Tweet )
5 years 6 months ago
New #therapeutic strategies in #SLE management
#EULAR2020 https://t.co/dhvTKd4EGB
dr hanady manasfi @hanadymanasfi ( View Tweet )
5 years 6 months ago
